Aim: It is not known if there is an association between resolution of ST-elevation to ST-depression following fibrinolysis and 30-day mortality. Methods: In an ECG substudy of HERO-2, which compared bivalirudin to unfractionated heparin following streptokinase in 12,556 patients with ST-elevation myocardial infarction ECGs were recorded at baseline and at 60 minutes after commencing fibrinolysis. The main outcome measure was 30-day mortality. Results: Using summed ST-segment elevation and five categories of changes in the infarct leads, further ST-elevation, 0−30% ST-resolution, >30−70% (partial) ST-resolution, >70% (complete) ST-resolution, and new ST-depression occurred in 21.7, 24.9, 36.8, 14.8, and 1.8% of patients, with 30-day mortality of 12.3, 11.7, 8.0, 4.2, and 8.1%, respectively. For the comparison of new ST-depression with complete ST-resolution and no ST-depression, p<0.01 with 24-hour mortality 4.5 vs. 1.3%, respectively (p=0.0003). Patients with new ST-depression had similar peak cardiac enzyme elevations as patients with complete ST-resolution without ST-depression. On multivariate analysis including summed ST-elevation at baseline, age, sex, and infarct location, new ST-depression was a significant predictor of 30-day mortality (OR 1.82, 95% CI 1.42−4.29).
Introduction
After the administration of reperfusion therapies for ST-elevation myocardial infarction (STEMI), resolution of ST-segment elevation in the infarct leads helps risk stratification. 1, 2 Although the use of primary percutaneous coronary intervention (PCI) is dominant in Western countries, the use of fibrinolysis is widely used worldwide and the incidence of myocardial infarction (MI) is increasing in developing countries 3 where many hospitals are non-PCI centres. In a recent meta-analysis, the prognostic meaning of early ST-resolution was found to be similar between fibrinolysis cohorts and primary PCI cohorts. 4 The use of a similar single lead measurement for ST-resolution is as informative as using summed ST-changes in all infarct leads both after fibrinolysis 5−7 and after primary PCI. 8 In the group of patients with complete ST-resolution, there may be heterogeneity in prognosis between patients with resolution of ST-elevation to an isoelectric level and resolution to a negative level with new ST-depression. We therefore analysed in the large Hirulog Early Reperfusion Occlusion (HERO)-2 mortality trial, which compared bivalirudin and unfractionated heparin in patients with STEMI receiving streptokinase for the significance of ST-resolution with new ST-depression.
Methods
The HERO-2 study randomized 17,073 patients with STEMI within 6 hours of symptom onset to receive bivalirudin or heparin, in addition to streptokinase and aspirin. 9 The randomized treatments had no effect on the primary endpoint of 30-day mortality. 9 The sites reported maximal cardiac enzyme levels (creatine kinase and creatine kinase MB) as multiples of the upper limit of normal in their sites; MIs were adjudicated by a blinded Clinical Events Committee (CEC). The protocol prespecified that a standard 12-lead ECG was to be performed at randomization and at 60 minutes after commencing streptokinase. 10−17 All ECGs were sent to the core laboratory at Green Lane Hospital for analysis by eight ECG technicians who were unaware of treatment assignment and patient outcomes. The evaluation of the prognostic significance of ST-segment changes at 60 minutes was prespecified by protocol.
ECG analysis
To qualify for this study, the baseline ECG had to be obtained no more than 2 hours before or 8 minutes after commencing streptokinase and the 60-minute ECG from 45 to 75 minutes after commencing streptokinase. ECGs with conduction abnormalities, ventricular or paced rhythms, or technical problems were excluded. The amount of ST-segment change was measured to the nearest 0.5 mm at 60 milliseconds after the J point. Only patients who had normal intraventricular conduction at both time points and had sufficient amount of baseline ST-elevation by core lab measurements (≥2 mm ST-elevation in 2 contiguous leads V1−3 or ≥1 mm ST-elevation in any other 2 contiguous leads) were eligible for the current study.
ST-resolution analysis
As prespecified by protocol, we used two ST-resolution analysis methods:
1. summed ST-elevation in the AMI leads showing any elevation ≥0.5 mm. For anterior AMI, the leads included I, aVL, and V1−V6. For inferior AMI, the leads included II, III, and aVF, and lateral leads V5, V6, I, and AVL 2. single lead ST-elevation using the lead with maximum elevation at baseline.
For analyses of changes in ST-elevation over 60 minutes in the infarct leads, five categories were defined:
1. further ST-elevation 2. no resolution of ST-elevation (0-30% resolution of baseline level) 3. partial resolution of ST-elevation of >30% -70% of baseline level 4. complete resolution of ST-elevation (>70% resolution of baseline level) but without developing ST-depression 5. new ST-segment depression ≥0.05mm developing in the infarct-leads.
Analysis for new ST-depression in the infarct leads
The same ECG infarct leads were measured on the baseline ECG and the 60-minute ECGs. If the ST-segment level was below the isoelectric line at 60 minutes (i.e. new ST-segment depression), it was read as a negative ST-level in the calculation of summed ST-elevation. For single lead analyses, the lead with the greatest ST-elevation at baseline was chosen for the paired measurements. If two infarct leads happened to show the same magnitude of baseline ST-elevation, the lead with deeper ST-depression at 60 minutes was used for paired analysis.
Statistical analysis
Comparison of variables was done by Wilcoxon rank-sum test or χ 2 test wherever appropriate. Discrete variables were reported as number and percentage and continuous variables were reported as median and the 25th and 75th percentiles where appropriate. The Kruskal−Wallis test was used to compare continuous variables among the different groups of ST-segment change at 60 minutes; the χ 2 test was used to compare discrete variables.
The primary aim of this study was to evaluate the relationship of new ST-depression at 60 minutes with 30-day mortality. A multivariable logistic regression model including summed ST-elevation at baseline, age, sex, infarction location, and ST-resolution was created first. Then clinical factors, including age and sex, geographic region of the patient recruitment, systolic blood pressure, Killip class, heart rate, infarct location, history of previous MI, diabetes, hypertension, prior angina and time to randomization, plus the ST-segment changes on the baseline ECG were entered into a full multivariable logistic regression model.
The five categories of ST-changes were regarded as categorical variables in both analyses. Nagelkerke's R 2 was used to estimate the variability in the dependent variable explained by the model and Hosmer−Lemeshow's goodness-of-fit test was conducted to determine whether the model fit was adequate. A C-statistic was used to determine the association of predicted probabilities and observed responses.
All analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA) and a significance level of α=0.05 was used to determine statistical significance for all comparisons.
The authors are solely responsible for the design and conduct of this study, the drafting and editing of the paper and its final contents. Analyses were performed by the authors. All patients gave informed consent to participate.
Results
Of 17,073 patients randomized in HERO-2, 12,556 patients had paired ECGs that satisfied our prespecified criteria for analysing ST-resolution and formed the cohort for the current report (Figure 1 ). Table 1 reports baseline characteristics of the 12,556 patients included in the ECG substudy and the 4517 patients excluded. The patients excluded were older, more likely had diabetes, presented later, and had higher mortality than the patients included in the ECG substudy. The 30-day mortality of the ECG cohort was 9.2% compared to 15.3% for the patients excluded. In the patients included in the substudy, the rate of angiography was 10.6%: 5.0% PCI and 0.6% coronary artery bypass grafting. Figure 2a and 2b show the increasing mortality rates according to the amount of summed ST-elevation and depression. Patients with new ST-depression were more likely to have a history of angina as compared with patients with complete ST-resolution (p=0.03). Multiples of the upper limit of normal (ULN) range for creatine kinase or creatine kinase MB were not different in patients with complete ST-resolution and no ST-depression vs. those with 
Development of new ST-depression
Using summed ST-levels in the infarct leads, 2050 patients had >70% ST-resolution. The 221 patients who developed new ST-depression in the infarct leads represented (10.8%) of patients with complete >70% ST-resolution. The median and interquartile range of summed ST-depression at 60 minutes in the infarct leads was 1.0 (0.5−1.5) mm. There was a trend for rates of reinfarction to be higher in patients with ST-depression compared to patients with >70% resolution and no ST-depression (6.3 vs. 3.9%, p=0.09; Table 3 ). Rates of combined death and reinfarction were higher in patients with new ST-depression compared with patients with >70% ST-resolution without ST-depression (14 vs. 7.7%, p=0.0012). Using the single lead with maximal baseline ST-elevation, mortality at 30-days was 9.1% in the 187 patients with new ST-depression and 4.8% in the 2240 patients with >70% ST-segment resolution without new ST-depression (p=0.01). Figure 3a shows the relative extent of ST-resolution and 30-day mortality and Figure 3b shows the residual ST-level and 30-day mortality.
Relationship between ST-resolution and 30day mortality

Multivariable predictors of 30-day mortality
In a multivariable analysis, including baseline summed ST-elevation, age, sex, and infarction location, new ST-depression was significantly associated with increased 30-day mortality when compared to ST-resolution >70% without ST-depression: (OR 1.82, 95% CI 1.42−4.29; Tables 4 and 5) . Tables 6 and 7 list the significant predictors for 30-day mortality when incorporating baseline variables, clinical factors, geographic region, and time to randomization in a multivariable model. For this model, the C index was 0.83. The location of the infarction, summed ST-elevation and summed ST-depression on the baseline ECG, and ST-segment changes at 60 minutes were all independent predictors. Compared to patients with >70% ST-resolution and no ST-depression, the 30-day mortality among those with new ST-depression was OR 1.77 (95% CI 0.97−3.24 compared to patients with ST-resolution 0-30% (no resolution; OR 0.67, 95% CI 0.38−1.19).
Discussion
The novel finding of this study is the prognostic significance of new ST-depression in the infarct leads following ST-resolution in patients receiving fibrinolytic therapy. A total of 221 patients (1.8% of the whole cohort and 10.8% of patients traditionally classified as having complete (>70%) ST-resolution) had ST-segment change from initial elevation to new depression in the infarct leads at 60 minutes after commencement of fibrinolytic therapy. This previously overlooked group of patients had an almost 2-fold higher 30-day mortality rate than those who achieved complete ST-resolution without new ST-depression. This finding remained significant following adjustment for baseline summed ST-elevation, age, sex, and infarct location. These are all factors that are readily available at the time of a 60-minute ECG. When a full multivariate analysis including all baseline factors, clinical factors, time to treatment, and geographic region was performed, the OR was 1.77 (95% CI 0.97−3.24).
The increased mortality was seen early within 24 hours with a trend to increased reinfarction rates and at 30 days. There was also an almost 2-fold increase in the 30-day rate of death and reinfarction. The resolution of ST-elevation suggests that epicardial and tissue reperfusion has occurred, 18 consistent with our findings that infarct size, as judged by peak cardiac enzyme elevations, was similar in patients with ST-resolution and new ST-depression to those with complete ST-resolution and no new ST-depression. The new ST-depression likely reflects ongoing ischaemia, such as from an infarct related artery lesion with a tight residual flow-limiting stenosis and/or clot microembolization plugging the microvasculature. Alternatively, ST-depression could have pre-existed before the AMI and with successful tissue reperfusion the ST-segments returned to the previous 'baseline' level. Both potential explanations for ongoing ischaemia are consistent with the increased 30-day incidence of combined death and reinfarction rates and the increased mortality within 24 hours as compared with patients with complete resolution without ST-depression. The findings are very relevant as fibrinolysis is the most common form of reperfusion used worldwide, with increasing numbers of patients requiring treatment for MI in developing countries, 3 particularly India where the prevalence of MI is increasing dramatically. 19 This large-scale ST-segment resolution study confirms previous findings. On the baseline ECG, the total amount of ST-elevation and the total amount of reciprocal ST-depression both reflecting potential infarct size had independent prognostic value. 20 Also early ST-change at 60 minutes after commencing fibrinolytic therapy added to baseline ST-changes in predicting mortality 4 by indicating the success or failure of reperfusion, both in the epicardial artery and at the tissue level. 18 The angiographic HERO-1 study found with continuous ST-monitoring among those with documented patent infarct-arteries an association between earlier ST-resolution and better infarct-zone wall motion at 48 hours, probably reflecting the result of better tissue reperfusion. 21 In the current analysis, up to five possible categories of ST-change (including further ST-elevation and new ST-depression) were used thereby incorporating the full spectrum of possible ST-changes, when assessing the ST-resolution was analysed as five categorical levels for the whole cohort as shown in Table 5 . relationship to 30-day mortality, which was the primary end-point of the HERO-2 study. This is a more rigorous approach than using either three levels (with 30 and 70% ST-resolution cut-points) or two levels (with 50%
ST-resolution cut-point) of ST-changes. ST-elevation reelevation occurred in a fifth of patients, and their 30-day mortality was numerically higher than those with no ST-resolution (OR 1.17, 95% CI 0.98−1.40). Guideline recommendations for 'routine' angiography after successful fibrinolysis have been evolving. The 2007 update of the ACC/AHA guidelines recommend coronary angiography with intent to perform rescue PCI is reasonable for patients in whom fibrinolytic therapy has failed (ST-segment elevation <50% resolved after 90 minutes following initiation of fibrinolytic therapy in the lead showing the worst initial elevation) and there is a moderate or large area of myocardium at risk (anterior MI, inferior MI with right ventricular involvement or precordial ST-segment depression): Class IIa, level of evidence B. 22 The recent 2010 guideline from the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery 23 recommends angiography within the first 24 hours following fibrinolytic therapy. However rapid transfer to a PCI centre for rescue angioplasty is recommended to be considered if ST-segment resolution is <50% based on studies showing the value of rescue angioplasty. 24, 25 Given that we found an increased 24-hour mortality risk among those with new ST-depression compared to those with otherwise complete ST-resolution, angiography and revascularization should also be considered among patients with new ST-depression even though resolution has occurred.
ST-segment depression at baseline in patients with STEMI undergoing primary PCI has attracted recent interest. The Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) investigators found resolution of ST-segment depression after primary PCI to be a good prognostic marker after primary PCI. 26 However, the APEX-AMI study did not address the development of new ST-depression after ST-segment resolution. ST-depression in patients with STEMI, particularly for patients with inferior MI, could be due to reciprocal changes from infero basal 27 or lateral involvement not fully captured by the standard 12-lead ECG, 28 thus explaining the favourable prognosis of ST resolution after primary PCI. The current report describes the new observation of infarct lead ST-segment levels changing from elevation to depression after fibrinolytic therapy and the relationship to increased mortality. It is unknown if this phenomenon is also seen after primary PCI.
Limitations
This study, which prospectively specified that ECGs be performed at baseline and at 60 minutes after beginning fibrinolytic therapy, was a post-hoc analysis in respect of analyses of new ST-depression. The study is limited by the fact that ECGs after 60 minutes were not collected. It is, thus, uncertain as to how new ST-depression might have evolved. Also we did not analyse the relationship between left ventricular hypertrophy and new ST-depression.
The study was in a cohort of patients receiving fibrinolysis with low rates of early angiography and angiographic findings are unknown. Also funding for mechanistic angiographic substudies was not available. In addition, the frequency of post-infarction angina was not collected. The statistical analysis was not corrected for multiple comparisons.
Conclusion
New ST-depression following complete ST-resolution after reperfusion with fibrinolysis is a novel and important marker for identifying patients at high risk of 30-day mortality. There is a need for further studies to confirm the prognostic value of our findings.
New ST-depression, likely reflecting ongoing ischaemia, identifies patients at higher risk than patients with otherwise complete ST-resolution. This additional parameter should be used in analysing ST-segment changes after patients have received fibrinolytic therapy and may be useful in triaging patients at high risk to early angiography and revascularization.
